These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
In-silico FDA-approved drug repurposing to find the possible treatment of Coronavirus Disease-19 (COVID-19).pdf (1.04 MB)

In-Silico FDA-Approved Drug Repurposing to Find the Possible Treatment of Coronavirus Disease-19 (COVID-19)

submitted on 20.05.2020, 15:52 and posted on 21.05.2020, 11:55 by Kumar Sharp, Dr. Shubhangi Dange
Identification of potential drug-target interaction for approved drugs serves as the basis of repurposing drugs. Studies have shown polypharmacology as common phenomenon. In-silico approaches help in screening large compound libraries at once which could take years in a laboratory. We screened a library of 1050 FDA-approved drugs against spike glycoprotein of SARS-CoV2 in-silico. Anti-cancer drugs have shown good binding affinity which is much better than hydroxychloroquine and arbidol. We have also introduced a hypothesis named “Bump” hypothesis which and be developed further in field of computational biology.


Email Address of Submitting Author


Government Medical College and Hospital, Jalgaon



ORCID For Submitting Author


Declaration of Conflict of Interest


Version Notes

Kindly send all corresponding to: Dr. Shubhangi Dange Associate Professor Department of Microbiology, Government Medical College and Hospital Jalgaon